# US 5,703,212 A · Preventive for circulatory diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,703,212 A
- Document ID: US5703212A
- Status: Granted
- Kind: A
- Application number: 08/727,426
- Filed: 1996-10-11
- Granted: 1997-12-30
- Earliest claimed: 1994-04-19
- Assignees: Kanebo, Ltd.
- Inventors: Ryuji Sugai; Umeji Murakami; Yukio Yamori
- Web page: https://patentgrep.com/patent/US5703212A

## CPC

- A61K 38/018: {from milk}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C07K 14/4732: {Casein (in foodstuffs A23J)}
- C12P 21/06: produced by the hydrolysis of a peptide bond, e.g. hydrolysate products (preparing foodstuffs by protein hydrolysis A23J3/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}

## Abstract

A preventive for circulatory diseases which can prevent the onset of circulatory diseases, particularly cerebral stroke, without causing adverse effects such as blood-pressure fluctuation. The preventive contains as the active ingredient a low-molecular-weight peptide fraction prepared by the trypsinization of casein followed by partial purification.

## Claims

### Claim 1

A preventive for cerebral stroke which comprises a low-molecular-weight peptide fraction available on partial purification of a trypsin digest of casein as an active ingredient.

### Claim 2 (depends on 1)

The preventive for cerebral stroke according to claim 1 wherein said casein is an acid casein, a salt of casein or rennet-casein.

### Claim 3 (depends on 1)

The preventive for cerebral stroke according to claim 1 wherein said trypsin is a trypsin of the reagent grade, of the pharmaceutical grade, or for a food additive.

### Claim 4 (depends on 1)

The preventive for cerebral stroke according to claim 1, wherein said trypsin digest is the product of a hydrolysis reaction carried out at pH 7.5 and a casein protein concentration of 10 weight % for 2 to 5 hours.

### Claim 5 (depends on 1)

The preventive for cerebral stroke according to claim 1, wherein said partial purification is carried out by using an ultrafiltration membrane or gel permeation chromatographic ligand with a peptide cutoff molecular weight of not greater than 5000.

### Claim 6 (depends on 1)

The preventive for cerebral stroke according to claim 1, wherein said partial purification is carried out by using an ultrafiltration membrane or gel permeation chromatographic ligand with a peptide cutoff molecular weight of not greater than 3000.

### Claim 7 (depends on 1)

The preventive for cerebral stroke according to claim 1, which is provided by incorporating a low-molecular-weight peptide fraction available on partial purification of a trypsin digest of casein in a proportion of 0.1 to 50 weight % based on the whole amount.

### Claim 8 (depends on 2)

The preventive for cerebral stroke according to claim 2 wherein said trypsin is a trypsin of the reagent grade, of the pharmaceutical grade, or for a food additive.

### Claim 9 (depends on 2)

The preventive for cerebral stroke according to claim 2 wherein said trypsin digest is the product of a hydrolysis reaction carried out at pH 7.5 and a casein protein concentration of 10 weight % for 2 to 5 hours.

### Claim 10 (depends on 3)

The preventive for cerebral stroke according to claim 3 wherein said trypsin digest is the product of a hydrolysis reaction carried out at pH 7.5 and a casein protein concentration of 10 weight % for 2 to 5 hours.

### Claim 11 (depends on 2)

The preventive for cerebral stroke according to claim 2 wherein said partial purification is carried out by using an ultrafiltration membrane or gel permeation chromatographic ligand with a peptide cutoff molecular weight of not greater than 5000.

### Claim 12 (depends on 3)

The preventive for cerebral stroke according to claim 3 wherein said partial purification is carried out by using an ultrafiltration membrane or gel permeation chromatographic ligand with a peptide cutoff molecular weight of not greater than 5000.

### Claim 13 (depends on 4)

The preventive for cerebral stroke according to claim 4 3 wherein said partial purification is carried out by using an ultrafiltration membrane or gel permeation chromatographic ligand with a peptide cutoff molecular weight of not greater than 5000.

### Claim 14 (depends on 2)

The preventive for cerebral stroke according to claim 2 wherein said partial purification is carried out by using an ultrafiltration membrane or gel permeation chromatographic ligand with a peptide cutoff molecular weight of not greater than 3000.

### Claim 15 (depends on 3)

The preventive for cerebral stroke according to claim 3 wherein said partial purification is carried out by using an ultrafiltration membrane or gel permeation chromatographic ligand with a peptide cutoff molecular weight of not greater than 3000.

### Claim 16 (depends on 4)

The preventive for cerebral stroke according to claim 4 wherein said partial purification is carried out by using an ultrafiltration membrane or gel permeation chromatographic ligand with a peptide cutoff molecular weight of not greater than 3000.

### Claim 17 (depends on 5)

The preventive for cerebral stroke according to claim 5 wherein said partial purification is carried out by using an ultrafiltration membrane or gel permeation chromatographic ligand with a peptide cutoff molecular weight of not greater than 3000.

### Claim 18 (depends on 2)

The preventive for cerebral stroke according to claim 2 which is provided by incorporating a low-molecular-weight peptide fraction available on partial purification of a trypsin digest of casein in a proportion of 0.1 to 50 weight % based on the whole amount.

### Claim 19 (depends on 3)

The preventive for cerebral stroke according to claim 3 which is provided by incorporating a low-molecular-weight peptide fraction available on partial purification of a trypsin digest of casein in a proportion of 0.1 to 50 weight % based on the whole amount.

### Claim 20 (depends on 4)

The preventive for cerebral stroke according to claim 4 which is provided by incorporating a low-molecular-weight peptide fraction available on partial purification of a trypsin digest of casein in a proportion of 0.1 to 50 weight % based on the whole amount.
